ACW — Actinogen Medical Share Price
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeSmall CapSucker Stock
- AU$126.01m
- AU$103.99m
- AU$0.03m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.13 | ||
| Price to Tang. Book | 5.81 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4,912.83 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -29.69% | ||
| Return on Equity | -36.73% | ||
| Operating Margin | -28590.45% | ||
Financial Summary
| Year End 30th Jun | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.16 | 0.09 | 0.2 | 0.09 | 0.03 | n/a | n/a | -33.25% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
12345678910
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Actinogen Medical Limited is an Australia-based biotechnology company. The Company is focused on developing therapy for neurological diseases associated with dysregulated brain cortisol. Its lead compound, Xanamem, is a therapy for Alzheimer's disease, fragile x syndrome, major depressive disorder and other neurological diseases. It is designed to block the production of cortisol the stress hormone in the brain. Xanamem is an inhibitor of the 11β-HSD1 enzyme that achieves target engagement in the central nervous system. It is an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Chronically elevated cortisol is associated with cognitive decline in Alzheimer’s Disease, linked to cognitive impairment and anxiety in Fragile X syndrome, and cognitive impairment in neuropsychiatric diseases. The Company focuses on developing Phase II clinical trial evaluating Xanamem in the treatment of cognitive impairment associated with Alzheimer.
Directors
- Geoffrey Brooke NEC
- Steven Gourlay CEO
- Jeff Carter CFO (60)
- Peter Webse SEC
- Malcolm Mccomas NED (65)
- George Morstyn NED (70)
- Last Annual
- June 30th, 2021
- Last Interim
- December 31st, 2021
- Incorporated
- March 26th, 1999
- Public Since
- October 12th, 2007
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 1,774,846,595
- Address
- Select House, SYDNEY, 2000
- Web
- http://actinogen.com.au/
- Phone
- +61 289647401
- Auditors
- Ernst & Young
Upcoming Events for ACW
Actinogen Medical Ltd Annual Shareholders Meeting
Similar to ACW
Adalta
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
Anatara Lifesciences
Australian Stock Exchange - SEATS
Anteotech
Australian Stock Exchange - SEATS
FAQ
What is the Actinogen Medical share price?
As of Today at 13:00 UTC, shares in Actinogen Medical are trading at AU$0.07. This share price information is delayed by 15 minutes.
How has the Actinogen Medical share price performed this year?
Shares in Actinogen Medical last closed at AU$0.07 and the price had moved by -17.44% over the past 365 days. In terms of relative price strength the Actinogen Medical share price has underperformed the ASX All Ordinaries Index by -17.71% over the past year.
What are the analyst and broker recommendations for Actinogen Medical?
There is no consensus recommendation for this security.
What is the Actinogen Medical dividend yield?
Actinogen Medical does not currently pay a dividend.
Does Actinogen Medical pay a dividend?
Actinogen Medical does not currently pay a dividend.
When does Actinogen Medical next pay dividends?
Actinogen Medical does not currently pay a dividend.
How do I buy Actinogen Medical shares?
To buy shares in Actinogen Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Actinogen Medical?
As of the previous close price of AU$0.07, shares in Actinogen Medical had a market capitalisation of AU$126.01m.
Where are Actinogen Medical shares listed?
Here are the trading details for Actinogen Medical:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: ACW
What kind of share is Actinogen Medical?
Based on an overall assessment of its quality, value and momentum Actinogen Medical is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Actinogen Medical share price forecast for 2022?
We could not find analyst target price data for this security.
What is the trend in the Actinogen Medical share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Actinogen Medical. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -45.79%.
As of the last closing price of AU$0.07, shares in Actinogen Medical were trading -36.79% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Actinogen Medical PE Ratio?
The Actinogen Medical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Actinogen Medical?
Actinogen Medical's management team is headed by:
- Geoffrey Brooke - NEC
- Steven Gourlay - CEO
- Jeff Carter - CFO
- Peter Webse - SEC
- Malcolm Mccomas - NED
- George Morstyn - NED